MMP9 Expression Correlates With Cisplatin Resistance in Small Cell Lung Cancer Patients

Background: Cisplatin is the basis of the primary treatment for SCLC chemotherapy. However, the limited objective response rate and definite drug resistance greatly restrict the clinical potential and therapeutic benefits of cisplatin use. Therefore, it is essential to identify biomarkers that can d...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Longqiu, Wang, Xiangcai, He, Xin, Li, Qiang, Hua, Qian, Liu, Rongrong, Qiu, Zhengang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010875/
https://www.ncbi.nlm.nih.gov/pubmed/35431936
http://dx.doi.org/10.3389/fphar.2022.868203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010875/
https://www.ncbi.nlm.nih.gov/pubmed/35431936
http://dx.doi.org/10.3389/fphar.2022.868203

Ejemplares similares